About developer_as

This author has not yet filled in any details.
So far developer_as has created 10 blog entries.

MedaPhor Group plc – Acquisition & Placing to raise £5.5m

This announcement contains inside information which, prior to its disclosure, was inside information for the purposes of the Market Abuse Regulation (Article 7 of Regulation (EU) No 596/2014. MedaPhor Group plc (“MedaPhor” or the “Group” or the “Company”) Acquisition and Placing Acquisition of deep-learning image analysis company, Intelligent Ultrasound, for up to £3.6m & Placing to raise £5.5m MedaPhor [...]

2017-09-20T10:33:33+00:00 September 20th, 2017|News|

Dosing of First Patient with investigational agent OMO-1

OCTIMET Oncology NV, the Belgian life science company with a focus on the development of MET kinase inhibitory drug candidates having additional differentiating properties, is pleased to announce the dosing of OMO-1 to the first patient. The multicenter, Phase I/II clinical trial (NCT03138083) is primarily evaluating the safety, pharmacokinetics and tolerability, alone and in combination [...]

2017-08-30T15:51:33+00:00 August 29th, 2017|News|

MedaPhor: Installation of 500th simulation system

MedaPhor Group plc (AIM: MED), the global provider of advanced ultrasound training simulators for medical professionals, announces it has sold its 500th simulation system, with the installation of a HeartWorks TTE Mobile echocardiography skills simulator at Penn State Health Milton S. Hershey Medical Center’s Clinical Simulation Center. MedaPhor’s ScanTrainer and HeartWorks product ranges offer clinicians [...]

2017-08-17T11:11:56+00:00 August 17th, 2017|News|

Verona Pharma Announces Pricing of Global Offering and Approval to List on the NASDAQ Global Market

April 27, 2017, LONDON - Verona Pharma plc (AIM: VRP) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, announces today the pricing of its global offering of an aggregate of 47,399,001 new ordinary shares, comprising 5,768,000 American Depositary Shares ("ADSs") at a price of $13.50 per ADS [...]

2017-05-01T21:44:28+00:00 April 27th, 2017|News|

Apitope Announces Positive ATX-MS-1467 Phase IIa Data in Relapsing Multiple Sclerosis

Hasselt, Belgium and Chepstow, UK: 21 February 2017 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, announces positive results from the Phase IIa clinical study of its lead product candidate, ATX-MS-1467, for the treatment of patients with multiple sclerosis. The Phase IIa, open-label, one arm study [...]

2017-03-21T22:17:29+00:00 February 21st, 2017|News|

Arthurian life sciences statement on reneuron stroke study results

Arthurian Life Sciences today welcomed the ‘highly encouraging’ findings of a significant clinical trial by ReNeuron, a global leader in the development of cell-based therapeutics. The PISCES II trial monitored improvement in arm movement as measured by the ARAT sub-test number two. The aim was to achieve discernible change within three months in two of [...]

2017-04-07T10:26:40+00:00 December 5th, 2016|News|